← Eichor
Study identifier: NCT07555691 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Yishen Shujin Decoction for Fibromyalgia Syndrome

Condition: Fibromyalgia Syndrome  ·  Sponsor: Juan Jiao

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This 24-week prospective study (12-week intervention + 12-week follow-up) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the therapeutic effects of YishenShujin Decoction, a clinically established herbal prescription, in patients with fibromyalgia (FM). The primary outcome is pain intensity measured by the Brief Pain Inventory (BPI). Secondary outcomes include improvements in the Fibromyalgia symptom scale(FS), revised Fibromyalgia Impact Questionnaire(FIQR), the Short Form-36 Health Status Questionnaire (SF-36), and FM-associated comorbidities. Safety profiles will be systematically monitored. In addition, brain structural and functional MRI will be used in this study to explore the underlying mechanisms.The findings aim to establish evidence for the formula's efficacy and provide insights into its role in FM management.

This description comes directly from the study's public registry record.

Talk to the study team

Juan Jiao  ·  010-88001132  ·  jiao.juan@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Guang'anmen Hospital of China Academy of Chinese Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07555691